The ARTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ARTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ARTH Detailed Price Forecast - CNN Money||View ARTH Detailed Summary - Google Finance|
|View ARTH Detailed Summary - Yahoo! Finance||View ARTH Stock Research & Analysis - Zacks.com|
|View ARTH Trends & Analysis - Trade-Ideas||View ARTH Major Holders - Barrons|
|View ARTH Call Transcripts - NASDAQ||View ARTH Breaking News & Analysis - Seeking Alpha|
|View ARTH Annual Report - CompanySpotlight.com||View ARTH OTC Short Report - OTCShortReport.com|
|View ARTH Fundamentals - TradeKing||View ARTH SEC Filings - Bar Chart|
|View Historical Prices for ARTH - The WSJ||View Performance/Total Return for ARTH - Morningstar|
|View the Analyst Estimates for ARTH - MarketWatch||View the Earnings History for ARTH - CNBC|
|View the ARTH Earnings - StockMarketWatch||View ARTH Buy or Sell Recommendations - MacroAxis|
|View the ARTH Bullish Patterns - American Bulls||View ARTH Short Pain Metrics - ShortPainBot.com|
|View ARTH Stock Mentions - StockTwits||View ARTH Stock Mentions - PennyStockTweets|
|View ARTH Stock Mentions - Twitter||View ARTH Investment Forum News - Investor Hub|
|View ARTH Stock Mentions - Yahoo! Message Board||View ARTH Stock Mentions - Seeking Alpha|
|View Insider Transactions for ARTH - SECform4.com||View Insider Transactions for ARTH - Insider Cow|
|View ARTH Major Holdings Summary - CNBC||View Insider Disclosure for ARTH - OTC Markets|
|View Insider Transactions for ARTH - Yahoo! Finance||View Institutional Holdings for ARTH - NASDAQ|
|View ARTH Stock Insight & Charts - FinViz.com||View ARTH Investment Charts - StockCharts.com|
|View ARTH Stock Overview & Charts - BarChart||View ARTH User Generated Charts - Trading View|
Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5
Posted on Wednesday September 05, 2018
Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today announced topline data for its irritation/sensitization patch test study of AC5™ Topical Gel (AC5)1. The study was designed to address a request by the Food and Drug Administration (FDA or “the Agency”). The objective of this Study (“Cumulative Irritancy Assay with Delayed Challenge for Allergic Contact Dermatitis Potential of AC5™ Topical Gel (AC5) in Healthy Volunteers”) was to assess irritation and sensitization potential (development of allergic contact dermatitis) of AC5 after repeat applications and then a delayed challenge application of the product to the skin.
FRAMINGHAM, Mass., Aug. 28, 2018-- Arch Therapeutics, Inc., developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the H.C. Wainwright 20 ...
Arch Therapeutics Announces Poster Presentation at the 2018 Military Health System Research Symposium on Tuesday, August 21, 2018
Posted on Thursday August 16, 2018
FRAMINGHAM, Mass., Aug. 16, 2018-- Arch Therapeutics, Inc., developer of AC5™ Topical Gel, today announced that new research involving AC5™ will be presented in a poster at the 2018 Military Health System ...
Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors
Posted on Friday July 20, 2018
Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™ (“AC5™”), today announced the appointment of Punit Dhillon, former President & CEO of OncoSec Medical, Inc. (ONCS), to its Board of Directors (the “Board”) as an independent member effective as of July 19, 2018. Mr. Dhillon brings over 15 years of global industry experience to Arch’s Board with a wealth of knowledge and experience operationally in medical devices, advancing programs from scientific research through clinical development, regulatory approval, and into healthcare systems globally. Mr. Dhillon is experienced and skilled in capital markets and in establishing strategic partnerships, including early and late stage deals with Merck and Pfizer.